Superoxide mediated isomerization of 4-aryl-but-1-ynes to 1-aryl-1,3-butadienes
摘要:
A new role of superoxide ion in the isomerization of homobenzylic acetylenes leading to 1-aryl-1,3-butadienes is reported. The unconventional reagent 1(02 is found to be superior in performing this kind of isomerization over other the commonly used bases. For substrates containing arene moiety and triple bond connected through more than two methylene groups, and for propargylcyclohexanol the reagent selectively effected migration of the triple bond. Reactivity of 1(02 towards the substrates having disubstitution at benzylic position varied depending on the nature of the substitution, alkyl-substitution lead to isomerization to give mixture of allene (an intermediate in the isomerization of acetylene to 1,3-butadiene) and triple bond migration product; whereas phenyl-substituted compound gave 1,3-diene. The utility of the methodology was demonstrated through a Diels-Alder reaction of one of the dienes obtained by the isomerization with suitable dienophiles. (C) 2015 Elsevier Ltd. All rights reserved.
Half-Sandwich Ruthenium Carbene Complexes Link<i>trans</i>-Hydrogenation and<i>gem</i>-Hydrogenation of Internal Alkynes
作者:Alexandre Guthertz、Markus Leutzsch、Lawrence M. Wolf、Puneet Gupta、Stephan M. Rummelt、Richard Goddard、Christophe Farès、Walter Thiel、Alois Fürstner
DOI:10.1021/jacs.8b00665
日期:2018.2.28
E-alkenes are formed by trans-delivery of the two H atoms of H2. A combinedexperimental and computational study now provides a comprehensive mechanistic picture: a metallacyclopropene (η2-vinyl complex) is primarily formed, which either evolves into the E-alkene via a concerted process or reacts to give a half-sandwich ruthenium carbene; in this case, one of the C atoms of the starting alkyne is converted
SeO<sub>2</sub>-Mediated Oxidative Transposition of Pauson–Khand Products
作者:Sara E. Dibrell、Michael R. Maser、Sarah E. Reisman
DOI:10.1021/jacs.9b13818
日期:2020.4.8
Oxidative transpositions of bicyclic cyclopentenones mediated by selenium dioxide (SeO2) are disclosed. Treatment of Pauson-Khand reaction (PKR) products with SeO2 in the presence or absence of water furnishes di- and trioxidized cyclopentenones, respectively. Mechanistic investigations reveal multiple competing oxidation pathways that depend on substrate identity and water concentration. Functionalization
SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF
申请人:CHENGDU MFS PHARMA. CO., LTD.
公开号:US20200369621A1
公开(公告)日:2020-11-26
A compound is shown in formula (I). The derivatives of the compound include a stereoisomer, a pharmaceutically acceptable salt, a solvate, a prodrug, a metabolite, a deuterated derivative. The compound is a structurally novel substituted imidazole formate derivative. Substituted imidazole formate derivatives are used in preparing a drug with sedative, hypnotic and/or anesthetic effects, as well as a drug that can control the state of epilepsy. The compound has a good inhibitory effect on the central nervous system, and provides a new option for clinical screening of and/or preparation of a drug with sedative, hypnotic and/or anesthetic effects and controlling the state of epilepsy.
Synthesis of Highly Substituted γ-Butyrolactones by a Gold-Catalyzed Cascade Reaction of Benzyl Esters
作者:Maria Camila Blanco Jaimes、Alexander Ahrens、Daniel Pflästerer、Matthias Rudolph、A. Stephen K. Hashmi
DOI:10.1002/chem.201402524
日期:2015.1.2
3‐butynoic acids in a gold‐catalyzed cyclization/rearrangement cascadereaction provided 3‐propargyl γ‐butyrolactones with the alkene and the carbonyl group not being conjugated. Crossover experiments showed that the formation of the new CC bond is an intermolecular process. Initially propargylic–benzylic esters were used, but alkyl‐substituted benzylic esters worked equally well. In the case of the propargylic–benzylic
[EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
申请人:GENENTECH INC
公开号:WO2016123391A1
公开(公告)日:2016-08-04
The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.